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PENILAIAN STATUS PENDAFTARAN TAHAP SEDIA ADA, CORAK 
PENGGUNAAN DAN RASIONAL KOMBINASI DRUG BERDOS TETAP DI 
NEPAL 
 
ABSTRAK 
Walaupun kombinasi ubat dengan dos tetap (Fixed dose drug combinations) 
menawarkan kebaikan tertentu dari segi komplian pesakit, kegunaannya menimbulkan 
banyak persoalan.  Penggunaannya di Nepal adalah meluas.  Walau bagaimanapun, 
tidak terdapat kajian yang ekstensif berkaitan kombinasi ubat dengan dos tetap.  Kajian 
ini menilai status pendaftaran, sejauh mana terdapatnya ubat ini, corak dan rasional 
penggunaannya di Nepal.  Pertama, status pendaftaran kombinasi ubat dengan dos tetap 
dalam senarai ubat kebangsaan dinilai dan sejauh mana terdapatnya ubat ini dalam 
Formulari Kebangsaan Nepal 1997, Senarai Model WHO bagi Ubat Perlu (edisi ke 15) 
2007 dan Senarai Ubat Perlu Nepal (semakan ketiga) 2002 telah dikaji. Kedua, sejauh 
mana terdapatnya ubat jenis ini yang tidak berdaftar di lima bandar utama di Nepal telah 
dijalankan menggunakan kaedah persampelan ‘snowball’ dengan melawat 20 kedai 
farmasi dalam setiap bandar.  Ketiga, kit alat yang telah dibangunkan oleh Health 
Action International-Asia Pacific (HAI-AP)  telah digunakan untuk memberi justifikasi 
ubat ini yang diperolehi dari lima bandar di Nepal.  Keempat, corak penggunaan ubat 
ini di institusi penjagaan kesihatan primer, sekunder dan tertiar dari kawasan barat 
Nepal telah dikaji menggunakan kaedah persampelan sistematik rawak melibatkan 100 
preskripsi dari setiap pusat penjagaan kesihatan primer, sekunder dan tertiar.  Dapatan 
kajian mendapati sebanyak 81 kombinasi ubat dengan dos tetap telah didaftarkan di 
Nepal.  Dari jumlah ini, peratusan yang tinggi (66.7%) daripada ubat ini diperolehi dari 
India.  Tujuh peratus dari pada 81 produk terdapat dalam Formulari Kebangsaan Nepal, 
 xviii
6.0% dalam Senarai Ubat Perlu Nepal dan 11.0% dalam Senarai Model WHO bagi Ubat 
Perlu.  Hanya 3 kombinasi hadir dalam semua formulari dan senarai ubat.  Sebanyak 41 
ubat tidak berdaftar diperolehi dari lima bandar.  Tidak ada satupun kombinasi ubat 
dengan dos tetap memenuhi kesemua keperluan fundamental sepertimana yang telah 
ditetapkan dalam kit alat.  Ini dapat diklasifikasikan sebagai tidak rasional.  Dalam 
pusat penjagaan kesihatan primer, 206 ubat telah dipreskripsikan dan 20.0% 
daripadanya adalah kombinasi ubat dengan dos tetap.  Ubat yang paling banyak 
dipreskripsikan adalah agen antimikrobial (57.1%).  Kos harga unit kesemua ubat 
adalah di bawah 100 NR (USD1=NR80).  Dalam pusat penjagaan sekunder, sebanyak 
309 ubat telah dipreskripsikan dan 30.0% adalah kombinasi ubat dengan dos tetap.  
Jenis kombinasi ubat dengan dos tetap yang paling banyak dipreskripsikan adalah 
vitamin, mineral dan makanan tambahan (25.8%).  Peratusan ubat dengan kos di bawah 
100 NR adalah 63.5%.  Bagi pusat penjagaan kesihatan tertiar pula,  33.7% daripada 
270 ubat yang telah dipreskripsikan adalah kombinasi ubat dengan dos tetap.  
Sepertimana di pusat penjagaan kesihatan sekunder, jenis kombinasi ubat dengan dos 
tetap yang paling banyak dipreskripsikan di pusat penjagaan kesihatan tertiar ini adalah 
vitamin, mineral dan makanan tambahan (40.6%).  Peratusan ubat dengan kos di bawah 
100 NR adalah 50.5%.  Sebagai kesimpulan, kajian ini mendapati banyak kombinasi 
ubat dengan dos tetap telah didaftarkan di Nepal.  Penggunaan yang agak ekstensif 
didapati di berbagai tahap pusat penjagaan kesihatan, di samping terdapatnya ubat yang 
tidak didaftarkan serta tidak rasional dalam pasaran farmaseutikal Nepal yang perlu 
dikeluarkan. 
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ASSESSMENT OF THE REGISTRATION STATUS, AVAILABILITY, 
UTILIZATION PATTERN AND RATIONALITY OF FIXED DOSE DRUG 
COMBINATIONS IN NEPAL 
 
 
ABSTRACT 
 
Fixed dose drug combinations (FDCs), though offer certain advantage in terms of 
patient compliance, their use is highly debatable. There is a widespread use of FDCs in 
Nepal. However, there are no extensive studies on FDCs. The present study evaluated 
the registration status, availability, utilization pattern and rationality of FDCs in Nepal. 
Firstly, registration status of FDCs in the national drug list was assessed and their 
availability in the Nepalese National Formulary (NNF) 1997, the WHO Model List of 
Essential medicines (15th Edition) 2007 and the Essential Drug List (EDL) of Nepal 
(third revision) 2002 were analyzed. Secondly, the availability of un-registered FDCs in 
five major cities of Nepal was carried out using a snowball sampling method with a 
visit of 20 retail pharmacies from each city. Thirdly, the toolkit developed by Health 
Action International-Asia Pacific (HAI-AP) was used to justify the rationality of the 
FDCs obtained from the five cities of Nepal. Fourthly, the utilization pattern of FDCs in 
primary health care (PHC), secondary health care (SHC) and tertiary health care (THC) 
centers from western Nepal was evaluated using systematic random sampling method 
involving 100 prescriptions from each health care center. A total of 81 FDCs were 
registered in Nepal. Higher percent (66.7%) of FDCs were from India. Among the total 
81 FDCs only, 7.0% were present in the NNF, 6.0% in the EDL of Nepal and 11.0% in 
the WHO Model List. Only three combinations were present in all the formularies and 
drug lists. Altogether, 41 un-registered FDCs were obtained from the five cities. None 
of the FDCs fulfilled all the fundamental requirements as stated in the toolkit, thus 
 xx
categorizing them to be ‘irrational’. In the PHC center, 206 drugs were prescribed 
among which 20.0% were FDCs. Antimicrobials were the highly prescribed FDCs 
(57.1%). The unit price costs of all FDCs were below 100 NRs (USD1=NRs 80). In the 
SHC center, 309 drugs were prescribed out of which 30% were FDCs. Vitamins, 
minerals and dietary supplements were highly prescribed FDCs (25.8%). The costs of 
63.5% of FDCs were below 100 NRs. In case of THC center, 33.5% were FDCs out of 
total 270 drugs prescribed. As in SHC center, vitamins, minerals and dietary 
supplements were highly prescribed FDCs (40.6%). The costs of 50.5% of FDCs were 
below 100 NRs. In conclusion, considerable amount of FDCs are registered in Nepal 
with extensive utilization in different levels of health care centers along with the 
availability of unregistered and irrational FDCs in Nepalese pharmaceutical market 
which needs to be weeded out. 
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 CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.0 Introduction  
1.1 Background 
The basic aim of pharmacotherapy is to treat a particular ailment with 
effective, safe and good quality medicines. Large proportions of the available drugs 
are of little importance in terms of essential and basic health care. There is no doubt 
that all the medicinal preparations are meant for the treatment of ailments and 
diseases, out of which only a few drugs are lifesaving and essential; rest of the drugs 
are substitutes for others (Sreedhar et al., 2006). Combination products which are 
also known as ‘fixed dose drug combinations’ (FDCs) are combination of two or 
more active ingredients in a single pharmaceutical dosage form (Gautam and Saha, 
2008). The United States Food and Drug Administration (US FDA) defines a 
combination product as a ‘product composed of any combination of a drug and a 
device or a biological product and a device or a drug and a biological product or a 
drug, device, and a biological product’ (Combination product definition 2007). The 
term ‘fixed-dose combination product’ is synonymous with ‘fixed-ratio combination 
product’. Both terms refer to a product that contains two or more active ingredients. 
Since the product is of defined composition, the two (or more) ingredients are 
present in a fixed ratio. Hence, the term ‘fixed dose’ or ‘fixed ratio’ combination is 
used (Regulation of fixed-dose combination products 2003). The availability, 
marketing, utilization pattern and rationality of FDCs are becoming increasingly 
important from a public health perspective.
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Combination therapy has been used since therapeutics was first practiced 
(Lyons and Petrucelli, 1987). Due to many reasons the use of FDCs are very 
common worldwide although many drugs are excellent when mingled and many are 
fatal (Manson and Routledge, 2005). It has become a very common practice for the 
physicians to prescribe polypharmacy. Though prescribed widely, the benefits of 
FDCs is debatable (Avijit, 2007). Many pharmacies demonstrate the popularity of 
FDCs over-the-counter (OTC) preparations, and more than one third of all new drug 
products introduced worldwide in 1978 were combination products or preparations, 
although there is an interesting variation between countries such as 10% in Japan to 
56% in Spain (Helfand, 1979). 
There are several advantages and disadvantages of FDCs. Potential 
advantages include: increased convenience for prescribers and patients, claimed to 
have a better patient compliance, considered to be cheaper as compared to a single 
product, logistics including procurement and distribution is easy (especially in the 
remote areas).  Potential disadvantages include: inflexible fixed dose ratio, 
incompatible pharmacokinetics, increased toxicity, and physician and pharmacist 
ignorance of content, and increased chance of adverse drug reactions (ADRs)  and 
drug interactions, encourage polypharmacy, drug resistance, some FDCs lead to 
abuse etc.  (McMahan, 1975; Poudel et al., 2008b; Shenfield, 1982). Although the 
existed FDCs possess several advantages and disadvantages, their availability is still 
skeptical. Whether the pharmaceutical companies make these FDCs because of the 
demand of the physicians or physicians prescribe multiple drugs because these 
dosage forms are easily available is a highly debatable issue (Avijit, 2007).        
Nepal is a landlocked country surrounded by India on three sides and China 
in the north. Its shape is roughly rectangular, about 850 kilometers long and about 
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200 kilometers wide, and comprises a total of 147 181 square kilometers of land. 
Nepal commonly is divided into three broad physiographic areas: ‘the Mountain 
Region’, ‘the Hilly Region’, and ‘the Terai Region’ also known as the ‘plain region’ 
and divided into five development regions: Eastern, Central, Western, Mid Western 
and Far Western region. Kathmandu is the capital city and is located in the Central 
development region.  The health system at national level consists of the Ministry of 
Health (MoH), Department of Health Services with its various divisions and units.  
Generally, the health care status of Nepalese population is poor. Health-care 
problems were varied and enormous. Poor health conditions were evident in the high 
rate of infant mortality- 48 per 1000 live births (2005), a short life expectancy at 
birth- 61 years (2004) and high maternal mortality- 281 per 10 000 live births (2006) 
(Nepal Health System Profile, 2007). There was no doubt that considerable progress 
has been made in health care, but the available facilities were still inadequate to 
meet the growing medical needs of the population. The preventive, curative, and 
promotive health services have been provided through 74 hospitals, 17 health 
centers, 79 primary health centers, 765 health posts and 2 588 sub-health posts, and 
47 950 community level health workers (Financing Drugs In South East Asia, 1996). 
The annual medicine consumption is over 3719.3 million Nepalese rupees 
(approximately US$ 46 million), with an estimated 28.5% rate of increase in 
consumption every year (Quantification of Drug Consumption in Nepal, 2006). 
Nepalese domestic pharmaceutical companies manufacture only 35.4% of medicines 
consumed in Nepal; rest is imported from foreign countries (Quantification of Drug 
Consumption in Nepal, 2006). The Department of Drug Administration (DDA) is a 
drug regulating body of Nepal. DDA regulates the import, export, procurement, 
sales, and manufacturing of the drug in the country.  
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1.2 Problem statement  
Many of the FDCs are harmful and a vast majority of them are irrational. The 
15th edition of WHO Model List of Essential Drugs contains 25 FDCs out of 352 
medicines in total (Poudel et al., 2008). The third revision of National Essential 
Drug list of Nepal (NEDL) contains 14 FDCs. Although, only a handful of essential 
FDC have been recognized by World Health Organization (WHO) and National 
Essential Drug List of Nepal, a wider variety of FDCs are available in the market 
today. Some FDCs increase the risk of side effects, lead to an ineffective dosage 
which are liable to abuse with potential for drug resistance and may also needlessly 
increase cost with reduction in quality of drug therapy (Beardshaw, 1983). FDCs are 
acceptable only when the dosage of each ingredient meets the requirements of a 
defined population group and when the combination has a proven advantage over 
single compounds administered separately in its therapeutic effects, safety or 
compliance. Because of the deficiency of a clear, comprehensive and rational drug 
policy and also lack of clear statement on the production and registration of FDCs, 
the irrational FDCs are booming in the market (Poudel et al., 2008b; Patel et al., 
2005). Often there is a competition among the drug companies to promote doctors to 
prescribe branded medicines in exchange for slight favors.  Such practice results in 
unnecessary prescription of drugs and combinations that are irrational including 
many irrational FDCs (Patel et al., 2005).  
No doubt that FDCs are popular among both patients and doctors, but always 
the reason behind this is not clear. On one hand physicians defend their right to 
prescribe FDCs (Davies and Wilson, 1975) and on the other hand regulatory 
authorities attempt to stop or restrict their use (Crout, 1975). Supporters of FDCs 
argue that the USFDA and WHO reports are made by bureaucrats and such 
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academicians who never treat patients and are not in direct contact with patients. 
According to them, they believe that drug companies have made adequate market 
research and they claim that patients readily take such drugs and that they must be 
effective or else they won’t be so popular (Budd, 1975). On the other hand, those 
who oppose to the concept of FDCs, argue that such preparations have little 
significance and a lot of dangers. According to them higher number of FDCs simply 
reflects public ignorance, lack of pharmacological knowledge by prescribers. They 
suggest that the marketing of such FDCs is based on a false philosophy that ‘if one 
is good, two is better, and three best of all’ (Shenfield, 1982). Studies from 
developing countries like Nepal have identified the use of FDCs in different health 
care settings (Joshi et al., 1997; Sarkar et al., 2004a; Rauniar et al., 2003). These 
studies are only preliminary and do not extensively study the FDCs. Moreover, there 
is no extensive study in Nepal on the availability, utilization pattern and rationality 
of FDCs. 
 
1.3 Literature review 
 A FDC refers to the combination of two or more drugs in a single 
pharmaceutical formulation. Rational FDCs can be of immense help to the health 
care system which may improve the quality of life for many. Meanwhile, irrational 
FDCs increase the risk of ADRs, lead to an ineffective dosages, and ultimately 
increases cost. In many cases their stability is doubtful, reducing the efficacy of 
many preparations. Several studies and papers in the literature indicate that FDCs 
are commonly utilized and prescribed in different health care centers in both 
developed and developing countries. FDCs are utilized as OTC to the prescription 
medicines in different health care centers. There are very few studies carried out in 
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these issues. Although there are very limited studies done in these areas, in this 
section we will try to review some of the published studies which are relevant to our 
objectives.  
 
1.3.1 Literature on registration status of fixed dose drug combinations 
 All the drugs that are registered in a country are for the prevention and 
treatment of diseases. In many countries, the drug production, distribution and 
registration is monitored by the drug controlling regulatory. There are some of the 
studies on requirements for combined pharmaceutical preparations but we were not 
able to assess the studies focusing specially on FDCs. 
 A comparison of the list of FDC therapies used in the USA, UK and Israel 
was carried out by Cohen et al., (2001). They counted the total list of drugs and 
FDC drugs manually from a list of generic names registered in the countries. They 
also counted the number of drugs in four characteristic subgroups: cardiovascular, 
anti-infective, gastrointestinal, and dermatological. Data for drugs in the USA, UK 
and Israel were taken from the Physician's Desk Reference (PDR 1997), the British 
National Formulary (BNF March 1997) and the Monthly Ethical Drug Indexed 
Compilation (MEDIC July 1997), respectively. FDC drugs in the USA and UK was 
higher than in Israel (20%, 25% and 15% respectively) and they found a similar 
trend was found in all subclasses of FDC drugs except for the anti-infective category 
in which the percentage of FDC drugs was low and similar in all countries. The list 
of FDC drugs varies greatly between the USA, UK and Israel, reflecting the 
differences in the outcome of debate between the pharmaceutical companies and the 
regulatory authorities. 
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1.3.2 Literature on availability of unregistered fixed dose drug combinations 
 A study by Poudel et al., (2008) from Nepal found that several unregistered 
FDCs are available in the pharmaceutical market and many of them were irrational. 
Although the study found the unregistered FDCs but the authors did not mention the 
reason behind their irrationality. It was a preliminary study which sensitized the 
issue to the regulatory authority.  
 Gautam and Aditya, (2006) found that Current Index of Medical Specialties 
(CIMS) and Monthly Index of Medical Specialties (MIMS), widely used by health 
care professionals list more than 100 IFDCs which are not approved in any 
developed countries but are being marketed in developing countries like Nepal and 
India. 
 
1.3.3 Literature on rationality of fixed dose drug combinations 
 Although some studies conclude that FDCs are registered and available in 
the country, they could not justify the rationality of the particular FDC. During our 
literature survey we could not come across studies mentioning a particular FDC as 
either ‘rational’ or ‘irrational’.  
 
1.3.4 Literature on utilization pattern of fixed dose drug combinations 
 A study from Ireland examined the prescribing pattern of the paracetamol-
containing analgesics in primary care (Usher et al., 2005). A national primary care 
prescribing database was used to investigate patterns of usage. Twenty-six thousand 
three hundred and eighteen patients who were new to therapy with paracetamol and 
paracetamol-containing analgesics between January and June 2002 were identified. 
FDC of paracetamol and dextropropoxyphene was the most commonly prescribed 
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analgesic, accounting for 42% of all prescriptions. Paracetamol-containing 
combination analgesics are widely prescribed but the use of FDC of paracetamol and 
dextropropoxyphene is particularly controversial. The results may indicate 
inappropriate use in primary care and suggest the need for educational programs 
highlighting the relative benefits and risks of use of such combination analgesics. 
Several analgesic preparations containing paracetamol and an opioid (such as 
codeine or dextropropoxyphene) available either via prescription only or for self-
medication via over-the-counter availability (such as FDC of paracetamol and 
ibuprofen) need to be justified as rational combinations. It requires further research 
since it has been reported that such combinations offers no substantial advantages in 
terms of safety and efficacy. 
 Pan et al., (2008) from the USA investigated the impact of FDC on 
adherence to prescription medications. Longitudinal data from a large claims 
database were used to assess adherence for one year. Authors found that the FDC 
enhanced adherence rates by approximately 13% when compared to a 2-pill 
regimen. But there are certain areas of controversy in the study. Only short term 
effects were measured. The generalizability of these results is limited. The study 
population included well-insured employees of large companies. Future studies may 
need to focus on individuals with less generous prescription drug coverage. Also, no 
information was available on length or severity of disease. 
 A retrospective study from a tertiary hospital in Nepal by Sarkar, and Das, 
(2000) analyzed the prescribing trend of different FDCs. An audit of the 
prescriptions revealed that 40% of the prescriptions contained FDCs however; FDCs 
in accordance with recommended DDA, Ministry of Health and WHO lists of FDCs 
were only 0.8% and 2.1%, respectively. The most commonly prescribed FDCs not 
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having any rational basis were multivitamins, cough and cold remedies and 
antimicrobials which constitute nearly 63% of total FDCs prescribed. Nearly 98% 
and 95% of the FDCs prescribed did not confirm to the recommended Nepal and 
WHO lists of FDCs, respectively. The study was able to address the scenario of 
FDCs utilization pattern in tertiary hospital but there were some controversies in the 
study. The authors concluded that although the FDCs are not included in the WHO 
list of FDC’s but meet certain criteria to be justified as rational, they should be 
designated as justified and rational FDC. So, a critical reappraisal is required and 
consensus should be attained at the scientific forums and regulatory authorities.  
 Sarkar et al., (2004) analyzed the analgesic use in dentistry in a tertiary 
hospital in Western Nepal. A total of 1820 prescriptions were analyzed where the 
total analgesics prescribed were 1358 that account for 36.7% of total drugs 
prescribed. A total of 38.9% analgesics were fixed-dose combinations (FDCs) of 
two drugs and the most common analgesic combination used was 
‘ibuprofen and paracetamol’ and ‘paracetamol and opioid analgesics’. All opioid 
analgesics were prescribed in combination with paracetamol. But the authors 
couldn’t justify the rationality of this combination drugs although they mentioned 
that it is best to avoid combination therapy with more than one non-opioid analgesic 
as there is little evidence of extra benefit to the patient and the incidence of side 
effects generally is additive. The issue is burning in developing countries like Nepal. 
The rationality behind the combination of NSAIDs should be justified which needs a 
further research in this area. 
 Another similar study by Das et al., (2003) evaluated drug use pattern during 
pregnancy in a teaching hospital in Western Nepal. Random collection of 2156 
prescriptions of pregnant women from the antenatal care in obstetrics Out-Patient 
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Department (OPD) at Manipal Teaching Hospital (MTH), Nepal was done. The 
average number of drugs per prescriptions was found to be 2 with 64.8% of drugs 
prescribed in the form of FDCs. Ideally, a woman should minimize taking drugs as 
soon as she plans to become pregnant or, when she suspects that she might be 
pregnant but according to this study the use of FDCs was rampant. These issues 
require further research and findings because only little information is available for 
the teratogenic potential of most FDCs (prescription as well as over-the-counter 
drugs).  
 A prospective study by Rauniar and Naga, (2003) analyzed a total of 467 
prescriptions collected from the inpatients of major specialties in a tertiary care 
teaching hospital, Nepal. Out of total 467 prescriptions, 206 (44.11%) prescriptions 
contained 276 FDC with a mean of 0.5 per prescription. Most commonly used FDCs 
were multivitamins (56.15%), analgesic (27.89%), antimicrobials (7.95%), antacids 
(3.98%) and cough mixtures (3.62%). The authors mentioned about the use of some 
irrational FDCs but they couldn’t justify on what basis they considered those FDCs 
as ‘irrational’ in the study.  
 Another study identified the drug prescribing practice of dentists in a tertiary 
care teaching hospital in western Nepal (Sarkar et al., 2004 b). A total of 1820 
prescriptions of dental patients were collected by a random once weekly survey. The 
information was compiled, scored and analyzed in consultation with dentists using 
WHO guidelines. The average number of drugs prescribed was 2.03 and 38% drugs 
were fixed dose combinations of two or more drugs. 
 A cross-sectional, descriptive study by Alam et al., (2006) teaching hospital 
in western Nepal analyzed the prescription of out-patients for rational prescribing 
and dispensing and evaluated the patient's knowledge regarding use of drugs, using 
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INRUD indicators. A total of 247 prescriptions were randomly selected for analysis, 
where 720 drugs were prescribed. Among the total, 21.7% of the total drugs 
consisted of FDCs, only 40% of drugs were from the Essential Drug List of Nepal 
and 29.44% were from the WHO Essential Drug List. Authors found that more than 
half (54.17%) of the drugs were from Nepalese National Formulary and 35.69% 
were from WHO Model Formulary. Dermatological products were most commonly 
prescribed followed by drugs acting on central nervous system, antimicrobials and 
drugs acting on cardiovascular system. The study had some limitations. It was 
conducted for a short period of time with limited sample size and seasonal variation 
was not evaluated. 
 A retrospective study on prescribing patterns for 100 randomly selected 
geriatric patients admitted over a period of one year to the medical wards of the 
Tribhuvan University Teaching Hospital (TUTH) in Nepal showed that the 
incidence of polypharmacy and FDCs was prevalent (Joshi et al., 1997). Authors 
found that during a hospital stay, 73% patients received more than five, 54% 
received more than eight, and 24% received more than nine drugs concurrently. 
Among the total drugs prescribed 15.4% drugs was FDCs. Relatively small number 
of patients in the study was observed as a limitation which made it difficult to 
directly extrapolate the findings to other hospitals.   
 Lamichhane et al., (2006) evaluated the morbidity profile and prescribing 
patterns among the outpatients in a teaching hospital in Western Nepal through a one 
year retrospective hospital record based study.  Altogether, 1261 cases were 
analyzed. The mean number of drugs was 1.99. Authors found that only 19.5% and 
39.6% of drugs were prescribed by generic name and from the Essential Drug List. 
Antibiotics were found to be commonly prescribed group of drugs. The most 
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commonly prescribed FDC antibiotics were ‘Amoxicillin and Cloxacillin’. The 
controversy in the study was found to be the use of this FDC of amoxicillin and 
cloxacillin. The FDC of ampicllin and cloxacillin often does not contain the requisite 
amount of each individual antibiotic. The combination is not synergistic as 
cloxacillin is not active against gram negative bacteria and does not inhibit beta 
lactamase while ampicillin is not active against staphylococci. Thus, the 
combination only adds to the cost and adverse effects of both drugs of the 
combination preparations, 19.6% of  preparations contained at least one NSAID, 
6.4% of preparations contained at least one antibiotic while 5.5% of preparations 
contained at least one corticosteroid. Some of the drug combinations being used 
were irrational. Prescriber education may be helpful in encouraging rational 
prescribing. 
 
1.4 Rationale of the study 
Only a few drugs that are available in a Nepalese pharmaceutical market are 
life saving and essential (Poudel et al., 2008b) the remaining are substitutes or 
alternative for others with around 65% of the medicines being imported from foreign 
countries and only around 1/3rd  being manufactured by domestic companies 
(Quantification of Drug Consumption in Nepal, 2006). For every drug to be 
registered in Nepal it should pass through the guidelines prepared by the drug 
regulatory authority (DDA) of Nepal. The DDA was established in the year 1979 
after the promulgation of Drug Act 1978, an act made for the regulation of drugs so 
as to prohibit the misuse or abuse of drugs and allied pharmaceutical materials as 
well as the false or misleading information relating to efficacy and use of drugs and 
to regulate and control the production, marketing, distribution, export-import, 
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storage and utilization of those drugs which are not safe for the use of the people, 
efficacious and of standard quality (Drug Act 2035 BS, 1978).  
Since past, the DDA has banned several medications for production, sale-
distribution and import in order to ensure safe use of medicines in Nepal. Few 
combination products such as FDCs of amidopyrin, phenacetin, clioquinol, 
combination containing two or more antihistamines, combination of antacid with 
vitamins or anti-inflammatory drugs and many more were banned (Official website 
of the department of drug administration, 2008). Although, the DDA have initiated 
some of the activities for banning these irrational combinations, they did not address 
the effective guidelines on the registration of the FDCs. 
Many FDCs are available in the Nepalese pharmaceutical market which is 
not listed in the drug list of Nepal (Poudel et al., 2008). Moreover, these 
combinations are available as Over The Counter (OTC) without a prescription. 
Many of these FDCs are considered to be irrational and are particularly prevalent in 
the plain lands of Nepal which is bordered with India. Studies from Nepal also 
concluded that there is an extensive utilization of FDCs in different health care 
settings (Lamichhane et al., 2006; Sarkar & Das, 2000). These FDCs are available 
for the treatment of various aliments ranging from nutritional deficiency to 
cardiovascular diseases (Poudel et al., 2008b). 
Since, these FDCs are available and are extensively utilized in Nepal, they 
need to be categorized as ‘rational’ or ‘irrational’ based on the availability of 
scientific evidences and literatures. Health Action International-Asia Pacific (HAI-
AP) an independent global network that is working to increase access to essential 
medicines and improve their rational use through research excellence and evidence-
based advocacy recently developed a toolkit to identify irrational FDCs (IFDCs). 
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This toolkit can be used as a standard reference to categorize a FDC as ‘rational’ or 
‘irrational’ (HAIAP, Advocacy and campaigns to remove irrational fixed dose 
combinations, 2008). 
 
1.5 Research questions 
 The overall study had the following research questions: 
a) Are all fixed dose drug combinations registered in Nepal and listed in different 
drug list and formularies of Nepal? 
 
b) To what extent do the unregistered fixed dose drug combinations available in 
Nepal? 
 
c) Are the unregistered fixed dose drug combinations which are available in Nepal 
rational? 
 
d) How are fixed dose drug combinations utilized in different levels of health care 
centers in Nepal? 
 
1.6 Study objectives 
 The present study was conducted based on the following general and specific 
objectives: 
 
General objective: To evaluate the registration status, availability, utilization 
pattern and rationality of fixed dose drug combinations (FDCs) in Nepal. 
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Specific objectives: 
a. To identify the registration status of all fixed dose drug combinations and their 
presence in informational formularies and drug lists in Nepal 
 
b. To carry out the market survey to assess the extent of availability of fixed dose 
drug combinations that are not registered in Nepal 
 
c. To evaluate the rationality of the various unregistered fixed dose drug 
combinations found from the market survey. 
 
d. To evaluate the utilization pattern of fixed dose drug combinations in primary, 
secondary and tertiary health care centers in Western Nepal. 
 
1.7 Significance of the study  
Research in these areas may also act as a cornerstone for a government to 
implement policy issues in use of FDCs as well as setting up criteria for the 
manufacturing and registering FDCs in particular countries. In Nepal, as such there 
are no such studies which have evaluated the registration status, availability and 
utilization status of FDCs in different health care settings. This study may act as a 
standard or as a reference for further researches in this area. Many researches are 
needed in these issues since several questions have not been answered in these areas.  
 
 
 
 
 15
 CHAPTER TWO 
EVALUATION OF THE REGISTRATION STATUS OF FIXED DOSE 
DRUG COMBINATIONS IN NEPAL 
 
2.1 Introduction 
2.1.1 Background 
 The main objective of the pharmaceutical policy of the vast majority of the 
countries is to ensure the access to essential, quality, effective and safe drugs, and 
that these drugs are used rationally. It is the responsibility of the government 
regulatory bodies through their national regulatory systems to assure that all drugs 
met criteria for quality, efficacy and safety.  Internationally, it is accepted that drug 
production and distribution require regulatory approval and supervision. These 
activities are divided into three components: a) product registration, including 
authorization for the marketing of drugs and monitoring of their efficacy and post 
marketing safety; b) regulation of drug production, importation, and distribution; 
and c) regulation of drug marketing and drug information (WHO medicines strategy, 
2004-2007; WHO, The world medicines situation, 2004). For a drug product to be 
registered in Nepal, several documents need to be submitted through the authorized 
Nepalese importer which contains information on detail formulation including 
recipients, color, flavor, product specification, methods of analysis, samples of the 
product (2-unit pack), labels and package, analytical reports, and many more 
(Requirements for Registration of Modern Medicines, 1981). For registering the new 
FDC and new molecule previously not registered in Nepal and or not included in 
recognized Pharmacopoeias, following information are required: a) Summary of 
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Product Characteristics (SPC); b) Name of the country, where the drug is marketed; 
c) Where and when the drug had been introduced in the home country; d) List of the 
other drugs having similar indication which are already marketed. If the new product 
fulfills the above mentioned criteria then they are registered in the Ministry of 
Health, DDA, Nepal (Registered drug products, 2008).     
 The Ministry of Health of Nepal in association with DDA published a 
formulary for the first time in the year 1997 as Nepalese National Formulary (NNF). 
The idea behind bringing the formulary was to identify the drug products needed for 
the country according to disease prevalence. NNF provides information on drugs 
and their dosage forms available in the country, with special emphasis on the 
essential drugs. It contains guidance on rational prescribing, classified notes on 
drugs, formulary based on the dosage forms and strength described in 
pharmacopoeias etc. (Nepalese National Formulary, 1997)  
 National List of Essential Drugs (NEDL) in Nepal was first published in 
1986. The list was revised in 1992, 1997 and 2002 [(National list of essential drugs 
Nepal (third revision), 2002)]. The fourth revision is under progress. Essential 
medicines are those that satisfy the priority health care needs of the population and 
are selected with due regard to disease prevalence, evidence on safety and efficacy, 
and comparative cost-effectiveness (Hogerzeil, 2004). Essential medicines are 
intended to be available within the context of functioning health systems at all times 
in adequate amounts, in the appropriate dosage forms, with assured quality, and at 
price the individual and the community can afford. (National List of Essential 
Drugs, fourth revision, 2009). Medicines are categorized as main and 
complementary in the national list. The complementary list represents essential 
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medicines for priority diseases, for which specialist medical care and/or specialist 
training and specialized diagnostic or monitoring facilities are required.  
 The WHO Model List of Essential Medicines has been widely adopted or 
adapted in over 150 countries (Essential Medicines, 2006). Large number of 
problems are associated with the utilization of therapeutic drugs in developing 
countries; inadequate access to cost effective drugs, poor procurement, poor 
management and distribution, irrational prescription and consumption. In response 
to these problems, the essential drug concept was introduced by WHO in the year 
1977 (Mandani & Walker, 1986). The 15th Edition of the Model List is divided 
into two parts which consist of the core list and the complementary list. The core list 
presents a list of minimum medicine needs for a basic health care system, listing the 
most efficacious, safe and cost-effective medicines for priority conditions. Priority 
conditions are selected on the basis of current and estimated future public health 
relevance, and potential for safe and cost-effective treatment. Similarly, the 
complementary list presents essential medicines for priority diseases, for which 
specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or 
specialist training are needed (WHO Model List of Essential Medicines 15th List, 
2007). The compilation of an essential medicines list enables health authorities, 
especially in developing countries, to optimize pharmaceutical resources.  
 
2.1.2 Problem statement 
 In developing countries like Nepal it is evident that the use of 
pharmaceuticals is not justified medically and economically (Jha et al., 2009). Both 
in the public and private sectors medicines and pharmaceuticals are often managed 
and used inefficiently and irrationally. This may be due to several reasons, but one 
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of the dominating factors may be the poor selection of medicines and not prescribing 
in accordance with the standard treatment and other guidelines (Holloway and 
Green, 2003). Those who are involved in the health sector decision making and the 
selection of drugs for the national health care objective must be concerned with the 
issues of irrational prescribing and cost effectiveness of the drug selected for as the 
essential drug for the particular countries. According to the fifteenth WHO Model 
List of essential medicines (March 2007), only 25 drug combinations are listed 
(approved). The latest version of the NEDL of Nepal approved only few FDCs 
(Poudel et al., 2008b). The FDCs account for 7% of the total drugs in the essential 
medicine list, whereas in Nepal a number of irrational drug combinations are easily 
available and can be bought without necessarily presenting a prescription (Official 
website of the DDA 2008; Gautam and Aditya, 2006). Meanwhile there are no any 
strict guidelines on registration of FDCs in Nepal.  
 
2.1.3 Rationale of the study 
 Registered drug list of Nepal contains the list of drug products with 
manufacturers including ingredients. It contains allopathic as well as ayurvedic 
preparations together with the price of each product. For a particular product to be 
registered in Nepal, it needs to pass through several measures. They should meet the 
criteria set up by the DDA. Considerable amount of FDCs are registered in drug list 
of Nepal. Selections of essential drugs are based on the aim to promote the rational 
use of medicines and ensure the availability of good quality medicines and economic 
brands. The presence of FDCs in the Essential Drug List of Nepal and NNF needs to 
be analyzed.  
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Prescribing doctors and health care professionals must be aware of the 
concept of Essential Drug List and formularies like NNF so as to promote rational 
prescribing and to eliminate the unnecessary use of several irrational drug 
combinations. A study covering five districts in Nepal revealed that 54% of clinical 
facility staff were not aware of the Essential Drug List (EDL) and 88% were not 
aware of the Standard Treatment Guidelines (STG) (Blum, 2002). Analyzing the 
registration status and the presence of FDCs in different drug list and informational 
formularies helps the utilization of rational FDCs which in turn aid in weeding out 
the irrational combinations booming in the pharmaceutical market.  The study is 
carried out for the first time in Nepal so the findings may also be beneficial for the 
appropriate policy changes. 
 
2.1.4 Study objectives 
This part of the study had the following research objectives: 
 
2.1.4.1 General objective 
 The general objective of the study was to evaluate the legality and 
registration status of the fixed dose drug combinations in the drug regulatory 
authority of Nepal. 
 
2.1.4.2 Specific objectives 
 The various specific objectives of the present study are as follows: 
1. To evaluate the registration status of fixed dose drug combinations in the national 
drug list of Nepal. 
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2. To evaluate the availability of fixed dose drug combinations in Nepalese National 
Formulary (NNF) 1997, WHO Model List of Essential Medicines (15th Edition) 
2007 and Essential Drug List of Nepal (third revision) 2002. 
 
3. To evaluate the therapeutic class of the fixed dose drug combinations registered in 
Nepal.  
 
2.2 Methodology 
2.2.1 Study design 
 Cross-sectional observational study evaluating the registration status of the 
fixed dose drug combinations in the drug list of Nepal and to evaluate their presence 
in informational formularies and drug lists. 
 
2.2.2 Inclusion and exclusion criteria 
 All the FDCs that are registered in the drug list of Nepal were included in the 
study. Several brands of same generic were considered as one FDC. For example, 
there were several brands of FDCs of paracetamol and ibuprofen in different 
strengths but considered it as a single FDC. FDCs of topical, intravenous and 
ayurvedic preparations were excluded from the study. The topical preparations 
contain drug combinations in indefinite doses so it will be almost impossible to 
categorize as either ‘rational’ or ‘irrational’ while the ayurvedic preparations usually 
don’t have any scientific justification for their efficacy. So, these preparations were 
excluded from the study. 
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2.2.3 Study tools 
 The various tools used in the study are as follows: 
 
i. Drug list of Nepal: The drug list of Nepal contains all the registered drug 
products along with the list of manufacturer including the ingredients. The drug list 
was obtained from the DDA through communications with the staff in the DDA. 
The drug list used in our study was updated till March 2008. 
 
ii. Nepalese National Formulary (NNF), 1997: NNF provides information on 
drugs and their dosage forms available in the country, with special emphasis on the 
essential drugs. It contains guidance on rational prescribing, classified notes on 
drugs, formulary based on the dosage forms and strength described in 
pharmacopoeias etc. The idea behind the publication of NNF was to identify the 
products needed for the country according to the diseases prevalence. A detailed list 
of drug interaction is also included in the formulary. 
 
iii. National list of essential drugs Nepal (third revision) 2002: National List of 
Essential Drugs was first published in 1986. The list was revised in 1992, 1997 and 
2002. It contains the list of drugs considered to be essential for Nepal. They are 
selected considering the disease prevalence, evidence on safety and efficacy, and 
comparative cost-effectiveness.  
 
iv. WHO Model List of Essential Medicines 15th List, 2007: The 15th Edition of 
the Model List is divided into two parts which consist of the core list and the 
complementary list.   
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2.2.4 Modality of operation 
 The registered drug list and the Nepalese National Formulary, 1997 was 
obtained from the Ministry of Health (MoH), Department of Drug Administration. 
The Essential Drug List of Nepal and the WHO Model List of essential medicines 
were obtained online through the internet and the below mentioned procedure was 
followed.  
 
FDCs registered in Nepal were separated from the main list 
 
 
 
 
Products of FDCs in Nepalese National Formulary 1997 was noted 
 
 
 
 
 
Products of FDCs in Essential Drug List of Nepal 2002 was noted 
 
 
 
 
Products of FDCs in WHO Model List of Essential Medicines 15th List, 2007 was noted 
 
 
Following this, a therapeutic classification of FDCs registered in Nepal was carried 
out. Finally the country of origin of FDCs that were registered in Nepal was 
analyzed. 
 
2.3 Results 
 A total of 81 FDCs were registered in Nepal at the time of March 2008. 
These 81 FDCs were further evaluated based on the study objectives. 
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2.3.1 Fixed dose drug combinations registered in Nepal 
 Among the total 42 manufacturers of FDCs, 66.7% (n= 28) of manufacturers 
were from India followed by 31.0% (n= 13) of manufacturers were from Nepal. The 
details are shown in Table 2.1. 
 
Table 2.1 Country of origin of fixed dose drug combinations registered in Nepal 
(n=42) 
Country of origin Frequency Percentage 
India 28 66.7 
Nepal 13 31.0 
Bangladesh 1 2.3 
 
 
2.3.2 Availability of fixed dose drug combinations in Nepalese National 
Formulary (NNF) 1997, WHO Model List of Essential Medicines (15th Edition) 
2007 and  Essential Drug List of Nepal (third revision) 2002 
 Among the total 81 FDCs registered in Nepal, only 7.0% (n= 6) were present 
in NNF, 6.0% (n= 5) were present in Essential Drug List of Nepal (3rd Revision 
2002) and 11.0% (n= 9) were present in WHO Model List of Essential medicines 
(15th Edition). Only three combinations; the combination of sulphamethoxazole and 
trimethoprim, the combination of pyrimethamine and sulfadoxine and the 
combination of ferrous sulphate and folic acid were present in all the formularies 
and drug lists. The details regarding the registration status of FDCs are shown in 
Table 2.2. 
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Table 2.2 Availability of fixed dose drug combinations in different informational formularies and drug lists (n= 81) 
Incidence in S. No Fixed dose drug combinations 
Nepalese 
National 
Formulary 
(NNF, 1997) 
Essential Drug List 
of Nepal 
(3rd Revision 2002) 
WHO Model List of 
Essential Medicines 
(15th Edition, 2007) 
1. Diloxanide Furoate+ Metronidazole ? X X 
2. Sulphamethoxazole + Trimethoprim ? ? ? 
3. Pyrimethamine + Sulfadoxine ? ? ? 
4. Amoxicillin + Clavulanate Potassium X X ? 
5. Ethinylestradiol + Levonorgesterol ? X ? 
6. Ethambutol + Isoniazid + Rifampicin X X ? 
7. Ethambutol + Isoniazid + Pyrazinamide + Rifampicin X X ? 
8. Lamivudine + Nevirapine + Stavudine X X ? 
9. Isoniazid + Rifampicin X ? ? 
10. Ferrous sulphate + Folic acid ? ? ? 
11. Aluminium hydroxide + Magnesium Trisilicate ? ? X 
 Total 6 (7%) 5 (6%) 9 (11%) 
Note:  ‘?’ denotes the presence, ‘X’ denotes absence
